What is PhoreMost?
Founded in 2014, PhoreMost operates at the intersection of advanced biology and computational drug discovery. The company's core technology, SITESEEKER, utilizes phenotypic screening to identify novel therapeutic targets that were previously considered undruggable. By systematically exploring the proteome, PhoreMost provides a robust framework for identifying small molecule inhibitors, effectively bridging the gap between academic research and clinical application. As a key player in the UK biotech ecosystem, the firm maintains a strategic focus on high-impact therapeutic areas, including oncology and neurodegeneration, where traditional discovery methods have historically faced significant bottlenecks.
How much funding has PhoreMost raised?
PhoreMost has raised a total of $68.8M across 3 funding rounds:
Angel/Seed
$3.8M
Series A
$15M
Series B
$50M
Angel/Seed (2015): $3.8M with participation from Cambridge Enterprise
Series A (2018): $15M, investors not publicly disclosed
Series B (2024): $50M supported by BGF, o2h ventures, Jonathan Milner, Parkwalk Advisors, XtalPi, Astellas Venture Management, The Morningside Group, and Trend Investments Group
Key Investors in PhoreMost
BGF
BGF is the most active and influential investor in small and mid-sized businesses in the UK, supporting a diverse range of growing companies across every sector of the economy.
Parkwalk Advisors
Parkwalk is a leading investor in university spinouts, focusing on deeptech innovations and bridging the gap between academic research and commercial success.
Astellas Venture Management
Astellas Venture Management is the corporate venture arm of Astellas Pharma, a global pharmaceutical company focused on the manufacturing and marketing of innovative medicines.
What's next for PhoreMost?
With the successful closure of this major enterprise-level funding round, PhoreMost is set to scale its operational capacity and deepen its research capabilities. The strategic roadmap involves the further validation of its internal drug discovery programs and the expansion of its commercial partnerships with global pharmaceutical entities. By utilizing this capital to enhance its proprietary screening infrastructure, the company aims to shorten the development cycle for first-in-class therapeutics. Investors are closely monitoring PhoreMost as it transitions from a research-intensive startup to a clinical-stage powerhouse, with a clear mandate to transform the standard of care for patients with high unmet medical needs.
See full PhoreMost company page
